BBIO Stock Recent News

BridgeBio's Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, far above consensus, and sees potential for nearly $1 billion in 2026 from existing patients alone.

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET.

- In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup with no prior history of AF compared to placebo

- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes

PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on May 9, 2025, the compensation committee of BridgeBio's board of directors approved equity grants to 36 new employees in restricted stock units for an aggregate of 101,974 shares of the Company's common stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in BridgeBio Pharma (BBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

- ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction) , establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM

PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated ePosters on the clinical outcomes and quality of life measures provided by acoramidis in variant transthyretin amyloid cardiomyopathy (ATTR-CM) and one moderated ePoster on a post-hoc analysis of the lower incidence rate of atrial fibrillation-related events in patients with ATTR-CM, all from the ATTRibute-CM study will be shared at the Annual Congress of the Heart Failure Association of the ESC (Heart Failure 2025), taking place in Belgrade, Serbia on May 17 - 20, 2025.

PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT.

BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Chinmay Shukla – Vice President-Strategic Finance Neil Kumar – Chief Executive Officer Matt Outten – Chief Commercial Officer Tom Trimarchi – President and Chief Financial Officer Ananth Sridhar – Chief Operating Officer-BridgeBio Cardiorenal Conference Call Participants Salim Syed – Mizuho Tyler Van Buren – TD Cowen Mani Foroohar – Leerink Partners Cory Kasimov – Evercore Greg Harrison – Scotiabank Paul Choi – Goldman Sachs Anupam Rama – JPMorgan Eliana Merle – UBS Jason Zemansky – Bank of America Operator Good afternoon. I will be your conference operator today.